Methods of determining acute myeloid leukemia response to...

Details Methods of determining acute myeloid leukemia response to... Methods of determining acute myeloid leukemia response to...

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01) G01N 33/68 (2006.01) C12Q 1/48 (2006.01)

Patent

CA 2680909

A simple two gene expression assay, RASGRPI:APTX, with utility in diagnosing a population of acute myeloid leukemia (AML) patients who are more likely to respond to farbesyltransferase inhibition with tipifamib (RI15777. ZARNESTRA).

L'invention concerne un simple dosage d'expression à deux gènes, RASGRPI:APTX, ayant une utilité dans le diagnostic d'une population de patients atteints de leucémie myéloïde aiguë (AML) plus susceptibles de répondre à une inhibition de la farnésyltransférase avec du tipifamib (RI15777. ZARNESTRA).

Affiliated with

Also associated with

Rating

Methods of determining acute myeloid leukemia response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of determining acute myeloid leukemia response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining acute myeloid leukemia response to... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1373624